TY - JOUR T1 - Radiation Dosimetry of <sup>99m</sup>Tc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1683 LP - 1687 VL - 45 IS - 10 AU - Naomi R. Schechter AU - Richard E. Wendt III AU - David J. Yang AU - Ali Azhdarinia AU - William D. Erwin AU - Anne M. Stachowiak AU - Lyle D. Broemeling AU - E. Edmund Kim AU - James D. Cox AU - Donald A. Podoloff AU - K. Kian Ang Y1 - 2004/10/01 UR - http://jnm.snmjournals.org/content/45/10/1683.abstract N2 - This study assessed the radiation dosimetry of 99mTc-labeled ethylene dicysteine (EC) C225 (EC-C225), a promising radioligand for functional tumor imaging. Methods: Whole-body scanning was performed on 6 patients with head and neck squamous cell carcinoma up to 24 h after administration of 99mTc-EC-C225. Alternate patients who had been randomized to receive C225 in a phase III trial received 99mTc-EC-C225 before their 20-mg test dose or after their 400 mg/m2 loading dose of unlabeled C225 (patients 1/3/5 and 2/4/6, respectively). Radiation dosimetry was assessed using the MIRD method. Results: The critical organ was the kidney, with an average radiation-absorbed dose for all 6 patients of 0.0274 mGy/MBq. The average total-body absorbed dose was 0.0022 mGy/MBq (0.243 cGy/1,110 MBq). Conclusion: The new radiopharmaceutical 99mTc-EC-C225 appears to have reasonable dosimetric properties for a diagnostic nuclear medicine agent. Correlation of the imaging results with clinical findings is the next step. ER -